Biotech Values

[DewDiligence]

NVS—Short NEJM video on the MoA of LCZ696 and the K-M curves from the PARADIGM-HF study:

http://www.nejm.org/action/showMediaPlayer?doi=10.1056/NEJMoa1409077&aid=NEJMoa1409077_attach_1

Valsartan, one of the two constituent drugs in LCZ696, is the generic name for Diovan, which was NVS’ largest-selling drug before it went off-patent in 2012.

David Epstein, NVS' head of pharmaceuticals, said on the 2Q14 CC that sell-side analysts are under-estimating the commercial potential of LCZ696, which is the kind of public remark that NVS almost never makes.